Cite
HARVARD Citation
Boyer, M. et al. (2021). Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of clinical oncology. 39 (21), pp. 2327-2338. [Online].